Mesentech

Mesentech is a clinical stage biotechnology company founded in 2016 and based in Canada. The company's slogan is "Clinical stage biotechnology company developing novel medicines that selectively distribute to the intended tissue." Mesentech is focused on developing novel medicines that selectively distribute to the intended site of action.

One of their key programs is MES1022, a clinical stage program for bone-repair being developed for 3 indications. In addition, Mesentech's preclinical pipeline includes novel compounds targeting bone-cancers. Their last funding round was a Venture Round investment at 01 January 2023, with Springhood being the investors involved.

Overall, Mesentech's focus on addressing unmet medical needs through selective drug distribution and their specific focus on bone-related treatments position them as a promising player in the biotechnology and healthcare industries.